FDA Grants Priority Review to the sNDA for Encorafenib in Combination with Cetuximab

The combination of encorafenib and cetuximab has shown promise in clinical testing for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation.

Read the full article here

Related Articles